Orchid Pharma

775.95
+0.05
(0.01%)
Market Cap
3,935.55 Cr
EPS
19.06
PE Ratio
35.74
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,997.40
52 Week Low
684.35
PB Ratio
3.22
Debt to Equity
0.25
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,751.50
#1 4,20,243.52
34.43
#1 49,887.20
12.06
#1 9,648
13.77
56.15
5,640.00
1,49,724.28
73.95
8,184.00
0.89
1,600
#1 64.53
49.32
1,515.20
1,22,369.82
24.22
26,520.70
14.17
4,155
47.38
58.14
3,254.80
1,10,157.22
58.55
10,785.70
11.59
1,656
13.54
57.00
2,581.60
1,06,511.27
50.98
10,615.60
19.57
1,942
-16.38
65.51
1,163.60
97,097.23
#1 18.01
28,905.40
12.36
5,578
1.69
53.92
1,937.20
88,441.11
30.81
20,141.50
#1 19.94
1,936
38.82
44.61
831.55
83,673.39
18.24
19,831.50
13.82
3,831
29.92
39.09
1,171.60
68,046.72
18.66
29,559.20
17.55
3,169
-10.04
56.33
30,690.00
65,214.11
48.91
6,097.20
10.80
1,201
16.01
56.24

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
24.06 %
Net Income Growth
72.28 %
Cash Flow Change
586.97 %
ROE
1.37 %
ROCE
-18.34 %
EBITDA Margin (Avg.)
10.70 %

Quarterly Financial Results

Quarterly Financials
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
141
138
137
93
120
110
105
131
95
196
164
180
134
171
169
251
185
207
228
231
252
230
226
Expenses
148
133
129
108
100
91
108
123
95
116
151
154
119
147
146
177
161
175
185
188
212
192
191
EBITDA
-7
6
7
-15
21
19
-3
8
0
79
13
26
15
24
23
74
24
32
43
42
40
38
35
Operating Profit %
-9 %
-1 %
0 %
-23 %
16 %
17 %
-5 %
-3 %
-3 %
9 %
7 %
13 %
10 %
11 %
9 %
16 %
12 %
12 %
16 %
13 %
13 %
14 %
12 %
Depreciation
31
32
32
23
30
30
29
20
20
20
20
27
22
18
8
7
8
8
9
8
8
9
9
Interest
0
0
3
1
14
13
13
12
11
10
7
5
8
9
8
8
6
4
4
4
4
3
4
Profit Before Tax
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-6
-14
-3
7
59
11
20
30
30
28
26
23
Tax
0
0
0
0
0
0
0
0
0
0
0
1
1
2
-1
0
1
0
1
-3
-1
-1
2
Net Profit
-39
-26
-28
-39
-23
-24
-45
-25
-31
49
-14
-7
-15
-5
8
59
9
20
29
33
29
27
21
EPS in ₹
-4.32
-2.93
-3.11
-9.52
-5.55
-5.98
-10.96
-6.06
-7.57
12.10
-3.40
-1.61
-3.68
-1.32
1.86
14.49
1.85
4.30
6.18
6.81
5.79
5.37
4.10

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
Fixed Assets
1,795
1,637
1,497
1,386
1,256
858
670
584
573
620
Current Assets
1,278
1,251
675
679
768
569
550
398
501
791
Capital Work in Progress
282
280
288
272
278
26
7
10
47
31
Investments
0
0
1
1
1
0
15
46
44
46
Other Assets
1,985
1,945
1,470
1,467
1,542
576
544
472
561
857
Total Liabilities
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
Current Liabilities
1,123
1,338
1,510
2,013
2,346
175
142
241
372
260
Non Current Liabilities
2,609
2,475
2,212
1,905
1,436
519
442
222
165
124
Total Equity
329
49
-467
-792
-704
766
653
647
689
1,170
Reserve & Surplus
244
-40
-556
-881
-793
725
544
538
579
1,050
Share Capital
85
89
89
89
89
41
41
41
41
51

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
367
-76
-240
15
57
-2
-74
-11
18
-19
Investing Activities
1,334
-2
-176
-28
46
167
67
113
-31
-312
Operating Activities
-369
212
401
9
12
81
24
93
18
126
Financing Activities
-597
-286
-465
33
-0
-250
-165
-217
31
167

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
98.07 %
90.00 %
90.00 %
90.00 %
90.00 %
89.96 %
89.96 %
89.96 %
89.96 %
72.40 %
72.40 %
69.84 %
69.84 %
69.84 %
69.84 %
69.84 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.14 %
1.96 %
1.42 %
1.94 %
2.53 %
DIIs
1.00 %
3.44 %
3.35 %
3.35 %
2.97 %
2.97 %
2.98 %
3.94 %
2.62 %
13.49 %
9.88 %
14.50 %
17.73 %
18.93 %
18.29 %
18.99 %
Government
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.58 %
2.34 %
2.72 %
2.83 %
3.34 %
3.69 %
3.61 %
3.44 %
3.38 %
3.10 %
3.85 %
7.79 %
7.44 %
7.16 %
7.59 %
6.42 %
Others
0.35 %
4.22 %
3.89 %
3.79 %
3.65 %
3.34 %
3.44 %
2.66 %
4.03 %
11.02 %
13.87 %
3.74 %
3.03 %
2.65 %
2.35 %
2.22 %
No of Share Holders
30,343
33,379
34,798
33,535
33,698
33,679
32,717
30,894
29,523
29,039
29,197
36,931
36,720
34,695
36,363
34,158

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20187 days ago
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements9 days ago
Intimation Of Letter(S)/Emails Received From Stock Exchanges As Cautionary Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Closure of Trading WindowMar 27, 2025
Intimation Under Regulation 30- Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And CreditorsMar 10, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 07, 2025
Disclosure Regarding The Order Passed By Goods And Service Tax DepartmentFeb 28, 2025
Disclosure Regarding The Order Passed By Goods And Service Tax DepartmentFeb 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2025
Statement Of Deviation Or Variation For The Quarter-III Of F.Y.2024-25 Ended On December 31 2024.Feb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Outcome Of The Board Meeting Held For Inter Alia Consideration And Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On DecembFeb 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On February 12 2025Feb 06, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Closure of Trading WindowDec 30, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024
Newspaper Publication Of Unaudited Limited ReviewedFinancial Results (Standalone & Consolidated) For Quarter- II And Half Year Ended On September 30, 2024 Of Financial Year 2024-25Nov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 11, 2024
Statement Of Deviation Or Variation For The Quarter Ended On September 30, 2024Nov 11, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2024
Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2024Nov 11, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On November 11, 2024Nov 11, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Board Meeting Intimation for Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended On September 30, 2024Nov 05, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 14, 2024
Intimation Related To The Scheme Of Amalgamation Of DhanukaLaboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company') And Their Respective Shareholders And Creditors ('The Scheme') Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 '(SEBI Listing Regulations)', As Amended.Sep 27, 2024
Intimation Of Email Received From BSE For Warning Letter Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Sep 27, 2024
Email Received From NSE Regarding Warning Letter Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI LODR )Sep 26, 2024
Closure of Trading WindowSep 25, 2024
Investor Roadshow Scheduled To Be Held On September 18, 2024Sep 11, 2024
Announcement under Regulation 30 (LODR)-Scheme of ArrangementSep 03, 2024
Disclosure Regarding The Order Passed By Goods And Service Tax DepartmentAug 22, 2024
Chairman Speech- 31St Annual General Meeting Of Orchid Pharma Limited Held On August 21, 2024Aug 22, 2024
Voting Results For The 31St Annual General Meeting Of Orchid Pharma LimitedAug 21, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAug 21, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 21, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 17, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2024
Monitoring Agency Report Of The Company For The Quarter-1 Of Financial Year 2024-25, Ended On June 30, 2024Aug 13, 2024

Technical Indicators

RSI(14)
Neutral
40.86
ATR(14)
Less Volatile
45.53
STOCH(9,6)
Neutral
36.35
STOCH RSI(14)
Overbought
100.00
MACD(12,26)
Bullish
15.11
ADX(14)
Strong Trend
26.67
UO(9)
Bearish
42.08
ROC(12)
Downtrend And Accelerating
-0.15
WillR(14)
Neutral
-38.61